Home Printer-friendly Register

About Genomic Health

Oncotype DX in Breast Cancer

Genomics in Cancer

Products and Services

Press Room

Investors
Stock Information
SEC Filings
Corporate Governance
Analyst Coverage
Event Calendar & Webcasts
Annual Report
FAQ
Email Alerts
Information Requests

Careers at Genomic Health

Contact Us

Investors

Corporate Profile
Genomic Health (Nasdaq: GHDX) is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In early 2004, we launched our first test under the brand name Oncotype DX® for early stage breast cancer patients. We believe that Oncotype DX is the first genomic test that has clinical evidence supporting its ability to predict the likelihood of cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit.

Recent Press Releases
May 8, 2008
Genomic Health to Present at Bank of America 2008 Healthcare Conference and 7th Annual JMP Securities Research Conference

May 6, 2008
Genomic Health Announces First Quarter 2008 Financial Results and Business Progress

All Press Releases

Webcasts
webcasts 7th Annual JMP Securities Research Conference
May 20th, 2008 - 1:00 PM PT / 4:00 PM ET
webcasts Bank of America 2008 Health Care Conference
May 14th, 2008 - 3:20 PM PT / 6:20 PM ET
webcasts First Quarter 2008 Financial Results
May 6th, 2008 - 1:30 PM PT / 4:30 PM ET
webcasts Morgan Stanley Global Healthcare Unplugged Conference
May 2, 2008 - 8:00 AM PT / 11:00AM ET
webcasts Leerink Swann Molecular Diagnostics Roundtable Conference
April 3, 2008 - 8:00 AM PT / 11:00AM ET
webcasts Lehman Brothers Global Health Conference
March 19th, 2008 - 2:15PM PT / 5:15PM ET
All Events and Webcasts

Forward Looking Statements
This website contains forward-looking statements based on certain assumptions and expectations. For this purpose, any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to our expectation that, for the foreseeable future, substantially all of our revenues will be derived from Oncotype DX; our dependence on collaborative relationships; the regulation of Oncotype DX by the FDA; our ability, and expectations as to the amount of time it will take, to achieve successful reimbursement from third-party payors and government insurance programs; and the attributes of our products; the outcome and success of clinical trials; and future financial results. For a discussion of other factors that may cause Genomic Health's actual results to differ from those projected, expressed or implied by the forward looking statements, please refer to the Company's Registration Statement on Form S-1 as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.



 

Virtual Investor/Media Kit

Fact Sheet (PDF)


Contact Information

For Investors:
650-569-2281
investors@genomichealth.com

For Media:
650-569-2215
media@genomichealth.com



Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

  Copyright © 2008 Genomic Health, Inc.  All rights reserved. | Contact Us | Site Map | Privacy | Terms and Conditions |